Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UUOGO
ADC Name
TORL-2-307-ADC
Synonyms
TORL-2-307 ADC; TORL-2-307- ADC; TORL-2-307- ADC, TORL-2-307-MAB; TORL-2-307-ADC; TORL-2-307-MAB
   Click to Show/Hide
Organization
TORL Biotherapeutics LLC
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05156866
Phase 1
A phase 1, first in human, dose-escalation study of TORL-2-307-ADC in participants with advanced cancer.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05156866  Clinical Status Phase 1
Clinical Description A phase 1, first in human, dose-escalation study of TORL-2-307-ADC in participants with advanced cancer.
References
Ref 1 A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer